What the FDA labels say about taking them together
Enzalutamide and ergotamine
Enzalutamide's FDA label (Xtandi) of May 25, 2021 names ergotamine in its drug interactions section; the ergotamine label PlainMeds reads does not name enzalutamide. The enzalutamide label: “Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4, CYP2C9 and CYP2C19 should be avoided, as enzalutamide may decrease their exposure.”
Check it at the source: the enzalutamide FDA label on DailyMed (effective July 28, 2026, Astellas Pharma US, Inc.); the ergotamine FDA label on DailyMed (effective February 25, 2025, Pangea Pharmaceuticals LLC).
What does the enzalutamide label say about ergotamine?
Xtandi label (Astellas Pharma US, Inc., May 25, 2021), drug interactionsConcomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin, clopidogrel) should be avoided, as enzalutamide may decrease their exposure.
Source: FDA drug label (Xtandi, NDA213674), Astellas Pharma US, Inc., effective May 25, 2021 (SPL set 381cd215-78c9-4208-8595-7ae7a279b236), via openFDA
Source: FDA drug label (Xtandi), Astellas Pharma US, Inc., effective July 28, 2026 (SPL set b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf), via openFDA; the full label on DailyMed
What does the ergotamine label say about enzalutamide?
Ergotamine's label (effective February 25, 2025) does not name enzalutamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ergomar Sublingual), Pangea Pharmaceuticals LLC, effective February 25, 2025 (SPL set a9582fdb-7ddd-4f69-aa7a-66247cdb8c92), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Enzalutamide | Ergotamine | |
|---|---|---|
| Labeled for | Prostate cancer | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $43.46 per tablet 2 mg tablet sublingual |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once